INMED PHARMACEUTICALS INC

ADAR1 Capital adds to its stake in InMed Pharmaceuticals, betting on the company’s single‑molecule cannabinoid platform and potential orphan drug breakthroughs.

ADAR1’s strategic stake in InMed, merging with Mentari, fuels migraine‑prevention growth—capital, IP, and market access converge for a biopharma upside.

ADAR1 Capital backs InMed Pharma’s CBD pipeline, with insider buying signaling confidence amid a merger; investors eye a potential rebound from today’s low.